A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 67
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : CAI
Long Form : carboxyamidotriazole
No. Year Title Co-occurring Abbreviation
2018 Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-BclxL strategies through Mcl-1 down-regulation. SOCE
2018 Metabolic Mechanisms and a Rational Combinational Application of Carboxyamidotriazole in Fighting Pancreatic Cancer Progression after Chemotherapy. 2-DG
2018 [Therapeutic effect and mechanism of carboxyamidotriazole on the pulmonary fibrosis of mice induced by bleomycin]. blank group, BLM group, IFN-gamma, MMP-9, PEG 400, TIMP-1
2017 Carboxyamidotriazole alleviates muscle atrophy in tumor-bearing mice by inhibiting NF-kappaB and activating SIRT1. LLC
2017 Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis. CI, NSCLC
2017 Therapeutic efficacy of carboxyamidotriazole on 2,4,6-trinitrobenzene sulfonic acid-induced colitis model is associated with the inhibition of NLRP3 inflammasome and NF-kappaB activation. DAI, IBD, IL, TNBS, TNF-alpha
2016 Carboxyamidotriazole inhibits oxidative phosphorylation in cancer cells and exerts synergistic anti-cancer effect with glycolysis inhibition. 2-DG, OXPHOS
2016 Therapeutic Effect of Carboxyamidotriazole on Adjuvant Arthritis in Rats. AA, AI, IL, TNF
2015 Activation of NALP1 inflammasomes in rats with adjuvant arthritis; a novel therapeutic target of carboxyamidotriazole in a model of rheumatoid arthritis. AA, NALP, RA
10  2015 Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases. cAMP-PDE, FRET, IBMX, LLC, PDE
11  2014 Store-operated Ca2+ entry does not control proliferation in primary cultures of human metastatic renal cellular carcinoma. ER, mRCC
12  2012 Carboxyamidotriazole ameliorates experimental colitis by inhibition of cytokine production, nuclear factor-kappaB activation, and colonic fibrosis. IBD, IL, NF-kappaB, TNF-alpha
13  2012 Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis. CML, CTO
14  2012 Inhibition of pro-inflammatory cytokines in tumour associated macrophages is a potential anti-cancer mechanism of carboxyamidotriazole. AA, DEX, LLC, TNF-alpha
15  2012 Store-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients. EPCs, RCC, TRPC1
16  2011 Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism. CML
17  2010 Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole. AMD, bHPCD, CNV, PDR, PK, ROP
18  2009 A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors. MTD, PR
19  2009 [Anti-inflammatory and analgesic potency of carboxyamidotriazole, a tumoristatic agent]. IL-beta, TNF-alpha, VEGF
20  2008 Anti-inflammatory and analgesic potency of carboxyamidotriazole, a tumorostatic agent. ---
21  2008 Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia. CML, IM
22  2008 Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). AE, NSCLC, QOL
23  2008 Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. MMR
24  2007 Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. CI, EIAED, GBM
25  2006 Carboxyamido-triazole inhibits proliferation of human breast cancer cells via G(2)/M cell cycle arrest and apoptosis. ---
26  2006 Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage. APOE, MCA, SAH
27  2005 Carboxyamido-triazole (CAI) reverses the balance between proliferation and apoptosis in a rat bladder cancer model. MNU, TCC
28  2005 Carboxyamido-triazole modulates retinal pigment epithelial and choroidal endothelial cell attachment, migration, proliferation, and MMP-2 secretion of choroidal endothelial cells. AMD, CECs, RPE
29  2005 Effective transscleral delivery of two retinal anti-angiogenic molecules: carboxyamido-triazole (CAI) and 2-methoxyestradiol (2ME2). ---
30  2005 Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study. RCC
31  2005 Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. RCC, RDT
32  2005 Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis. ---
33  2004 A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer. ---
34  2004 CAI is a potent inhibitor of neovascularization and imparts neuroprotection in a mouse model of ischemic retinopathy. PEG 400, PND
35  2004 Carboxyamido-triazole (CAI), a signal transduction inhibitor induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2. TCC
36  2004 The blocking of capacitative calcium entry by 2-aminoethyl diphenylborate (2-APB) and carboxyamidotriazole (CAI) inhibits proliferation in Hep G2 and Huh-7 human hepatoma cells. 2-APB, CCE, NCCE
37  2004 [Carboxyamido-triazole inhibits substeps of choroidal neovascularization on retinal pigment epithelial cells and choroidal endothelial cells in vitro]. AMD, CECs, RPE cells
38  2003 CAI inhibits the growth of small cell lung cancer cells. BB, NT, SCLC, VEGF
39  2003 Control of endothelial cell proliferation by calcium influx and arachidonic acid metabolism: a pharmacological approach. AA, cPLA2, LOX
40  2003 Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. IL, MMP, VEGF
41  2003 Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole. HUVEC, IL-8, VEGF
42  2002 Essential role of calcium in vascular endothelial growth factor A-induced signaling: mechanism of the antiangiogenic effect of carboxyamidotriazole. MAP kinase, NFAT, NO, VEGF-A, VEGFR2
43  2002 Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. ---
44  2002 Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. MTD
45  2001 A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction. PAX
46  2001 Carboxyamido-triazole (CAI)--a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells. CLL
47  2001 Vascular endothelial growth factor-A activates Ca2+ -activated K+ channels in human endothelial cells in culture. bFGF, VEGF-A
48  2000 Calcium mobilization is required for spreading in human osteoblasts. ---
49  2000 Carboxyamido-triazole induces apoptosis in bovine aortic endothelial and human glioma cells. ---
50  2000 Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway. HAECs, NOS, VEGF
51  2000 Screening assay for promigratory/antimigratory compounds. ---
52  1999 A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer. ---
53  1998 Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI). ---
54  1998 Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters. PK
55  1997 Antiproliferative and antiinvasive effects of carboxyamido-triazole on breast cancer cell lines. ---
56  1997 New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12. IL
57  1997 Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations. MR
58  1997 Selective inhibition of mitogen-induced transactivation of the HIV long terminal repeat by carboxyamidotriazole. Calcium influx blockade represses HIV-1 transcriptional activation. HIV, LTR
59  1997 Thapsigargin-induced gene expression in nonexcitable cells is dependent on calcium influx. ---
60  1996 Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. ---
61  1996 Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. ---
62  1995 Angiogenesis: role of calcium-mediated signal transduction. HUVECs
63  1995 In vitro and in vivo myelotoxicity of CAI to human and murine hematopoietic progenitor cells. BFU-e, CFU-GM
64  1995 Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction. Tmax
65  1995 Quercetin: synergistic action with carboxyamidotriazole in human breast carcinoma cells. ---
66  1994 Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). MMP, TGF-beta1
67  1993 Quantitation of human plasma levels of the anticancer agent carboxyamidotriazole by high-performance liquid chromatography. ---